Premium
Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders
Author(s) -
Gordon Mark Forrest,
DiazOlivo Rolando,
Hunt Ann L.,
Fahn Stanley
Publication year - 1993
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.870080412
Subject(s) - myoclonus , parkinsonism , dystonia , movement disorders , medicine , dyskinesia , adverse effect , progressive supranuclear palsy , etiology , levodopa , anesthesia , physical medicine and rehabilitation , parkinson's disease , psychiatry , disease
We performed a therapeutic trial with the glycine precursor, milacemide, on 10 patients with intractable movement disorders. Six had myoclonus of various etiologies and one each had progressive supranuclear palsy, Filipino X‐linked dystonia with parkinsonism, painful legs and moving toes, and stiff‐person syndrome. Milacemide was initiated at a dose of 2,400 mg/ day, orally, and increased gradually to a maximum of 4,800 mg/ day. No clear‐cut observable improvement occurred. There were no serious adverse effects.